<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01019694</url>
  </required_header>
  <id_info>
    <org_study_id>1012.62</org_study_id>
    <nct_id>NCT01019694</nct_id>
  </id_info>
  <brief_title>Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>Patient Acceptability of Ipratropium Bromide/Albuteroll Delivered by the RespimatÂ® Inhaler in Adults With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate long-term safety and patient acceptability
      of COMBIVENT RESPIMAT Inhalation Spray as compared to the COMBIVENT Inhalation Aerosol
      Chlorofluorocarbon-Metered Dose Inhaler (CFC-MDI) and the free combination of ATROVENT
      Hydrofluoroalkane (HFA) and albuterol Hydrofluoroalkane (HFA) inhalation aerosols.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Performance Domain Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 48</measure>
    <time_frame>48 weeks</time_frame>
    <description>Patient acceptability was assessed with the Performance Domain score from the PASAPQ. The score is a mean of 7 items on a scale from 0 (very dissatisfied) to 100 (very satisfied).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Performance Domain Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 3</measure>
    <time_frame>3 weeks</time_frame>
    <description>Patient acceptability was assessed with the Performance Domain score from the PASAPQ. The score is a mean of 7 items on a scale from 0 (very dissatisfied) to 100 (very satisfied).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance Domain Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Patient acceptability was assessed with the Performance Domain score from the PASAPQ. The score is a mean of 7 items on a scale from 0 (very dissatisfied) to 100 (very satisfied).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance Domain Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Patient acceptability was assessed with the Performance Domain score from the PASAPQ. The score is a mean of 7 items on a scale from 0 (very dissatisfied) to 100 (very satisfied).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance Domain Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 36</measure>
    <time_frame>36 weeks</time_frame>
    <description>Patient acceptability was assessed with the Performance Domain score from the PASAPQ. The score is a mean of 7 items on a scale from 0 (very dissatisfied) to 100 (very satisfied).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 0</measure>
    <time_frame>0 weeks</time_frame>
    <description>Patient satisfaction was assessed by asking: &quot;Overall, how satisfied are you with your inhaler?&quot;. Responses were made on a scale from 1 (very dissatisfied) to 7 (very satisfied).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 3</measure>
    <time_frame>3 weeks</time_frame>
    <description>Patient satisfaction was assessed by asking: &quot;Overall, how satisfied are you with your inhaler?&quot;. Responses were made on a scale from 1 (very dissatisfied) to 7 (very satisfied).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Patient satisfaction was assessed by asking: &quot;Overall, how satisfied are you with your inhaler?&quot;. Responses were made on a scale from 1 (very dissatisfied) to 7 (very satisfied).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Patient satisfaction was assessed by asking: &quot;Overall, how satisfied are you with your inhaler?&quot;. Responses were made on a scale from 1 (very dissatisfied) to 7 (very satisfied).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 36</measure>
    <time_frame>36 weeks</time_frame>
    <description>Patient satisfaction was assessed by asking: &quot;Overall, how satisfied are you with your inhaler?&quot;. Responses were made on a scale from 1 (very dissatisfied) to 7 (very satisfied).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 48</measure>
    <time_frame>48 weeks</time_frame>
    <description>Patient satisfaction was assessed by asking: &quot;Overall, how satisfied are you with your inhaler?&quot;. Responses were made on a scale from 1 (very dissatisfied) to 7 (very satisfied).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 0</measure>
    <time_frame>0 weeks</time_frame>
    <description>CCQ symptom domain score assessed patient feelings or limitations due to their COPD on a scale from 0 (not limited) to 6 (totally limited).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 3</measure>
    <time_frame>3 weeks</time_frame>
    <description>CCQ symptom domain score assessed patient feelings or limitations due to their COPD on a scale from 0 (not limited) to 6 (totally limited).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>CCQ symptom domain score assessed patient feelings or limitations due to their COPD on a scale from 0 (not limited) to 6 (totally limited).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>CCQ symptom domain score assessed patient feelings or limitations due to their COPD on a scale from 0 (not limited) to 6 (totally limited).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 36</measure>
    <time_frame>36 weeks</time_frame>
    <description>CCQ symptom domain score assessed patient feelings or limitations due to their COPD on a scale from 0 (not limited) to 6 (totally limited).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 48</measure>
    <time_frame>48 weeks</time_frame>
    <description>CCQ symptom domain score assessed patient feelings or limitations due to their COPD on a scale from 0 (not limited) to 6 (totally limited).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's Global Evaluation at Week 0</measure>
    <time_frame>0 weeks</time_frame>
    <description>Physicians evaluated the patient's overall clinical condition on a scale ranging from &quot;poor&quot; (score 1 or 2) to &quot;excellent&quot; (score 7 or 8).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's Global Evaluation at Week 3</measure>
    <time_frame>3 weeks</time_frame>
    <description>Physicians evaluated the patient's overall clinical condition on a scale ranging from &quot;poor&quot; (score 1 or 2) to &quot;excellent&quot; (score 7 or 8).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's Global Evaluation at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Physicians evaluated the patient's overall clinical condition on a scale ranging from &quot;poor&quot; (score 1 or 2) to &quot;excellent&quot; (score 7 or 8).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's Global Evaluation at Week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Physicians evaluated the patient's overall clinical condition on a scale ranging from &quot;poor&quot; (score 1 or 2) to &quot;excellent&quot; (score 7 or 8).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's Global Evaluation at Week 36</measure>
    <time_frame>36 weeks</time_frame>
    <description>Physicians evaluated the patient's overall clinical condition on a scale ranging from &quot;poor&quot; (score 1 or 2) to &quot;excellent&quot; (score 7 or 8).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's Global Evaluation at Week 48</measure>
    <time_frame>48 weeks</time_frame>
    <description>Physicians evaluated the patient's overall clinical condition on a scale ranging from &quot;poor&quot; (score 1 or 2) to &quot;excellent&quot; (score 7 or 8).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FEV1 at Day 1</measure>
    <time_frame>baseline, day 1</time_frame>
    <description>Change from test-day baseline in Forced Expiratory Volume in 1 second (FEV1) at 1 hour post dose on test day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FEV1 at Week 12</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>Change from test-day baseline in Forced Expiratory Volume in 1 second (FEV1) at 1 hour post dose at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FEV1 at Week 24</measure>
    <time_frame>baseline, 24 weeks</time_frame>
    <description>Change from test-day baseline in Forced Expiratory Volume in 1 second (FEV1) at 1 hour post dose at Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FEV1 at Week 48</measure>
    <time_frame>baseline, 48 weeks</time_frame>
    <description>Change from test-day baseline in Forced Expiratory Volume in 1 second (FEV1) at 1 hour post dose at Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FVC at Day 1</measure>
    <time_frame>baseline, day 1</time_frame>
    <description>Change from test-day baseline in Forced Vital Capacity (FVC) at 1 hour post dose on test day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FVC at Week 12</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>Change from test-day baseline in Forced Vital Capacity (FVC) at 1 hour post dose at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FVC at Week 24</measure>
    <time_frame>baseline, 24 weeks</time_frame>
    <description>Change from test-day baseline in Forced Vital Capacity (FVC) at 1 hour post dose at Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FVC at Week 48</measure>
    <time_frame>baseline, 48 weeks</time_frame>
    <description>Change from test-day baseline in Forced Vital Capacity (FVC) at 1 hour post dose at Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 0</measure>
    <time_frame>0 weeks</time_frame>
    <description>Mean number of puffs of daily rescue medication use (albuterol use per 24 hour period) in two weeks prior to week 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 3</measure>
    <time_frame>3 weeks</time_frame>
    <description>Mean number of puffs of daily rescue medication use (albuterol use per 24 hour period) in two weeks prior to week 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean number of puffs of daily rescue medication use (albuterol use per 24 hour period) in two weeks prior to week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Mean number of puffs of daily rescue medication use (albuterol use per 24 hour period) in two weeks prior to week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 36</measure>
    <time_frame>36 weeks</time_frame>
    <description>Mean number of puffs of daily rescue medication use (albuterol use per 24 hour period) in two weeks prior to week 36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 48</measure>
    <time_frame>48 weeks</time_frame>
    <description>Mean number of puffs of daily rescue medication use (albuterol use per 24 hour period) in two weeks prior to week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Having Chronic Obstructive Pulmonary Disease (COPD) Exacerbations</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Having Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Leading to Hospitalization</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">470</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Combivent Respimat 20/100 microgram(mcg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to take 1 inhalation 4 times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combivent CFC-MDI 36/206 microgram-mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient to take 2 inhalations 4 times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atrovent HFA 42 mcg + Albuterol HFA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient to take 2 inhalations of each 4 times a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combivent CFC-MDI</intervention_name>
    <description>36/206 mcg Four times a day (QID)</description>
    <arm_group_label>Combivent CFC-MDI 36/206 microgram-mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combivent Respimat 20/100 mcg</intervention_name>
    <description>Open label randomized parallel</description>
    <arm_group_label>Combivent Respimat 20/100 microgram(mcg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atrovent HFA 42 mcg + Albuterol HFA 200 mcg</intervention_name>
    <description>Open label randomized parallel</description>
    <arm_group_label>Atrovent HFA 42 mcg + Albuterol HFA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. All patients must sign an informed consent consistent with International Conference on
             Harmonization (ICH) Good Clinical Practice (GCP) guidelines prior to participation in
             the trial.

          2. Male or female patients 40 years of age or older.

          3. Patients must be current or ex-smokers with a smoking history of 10 pack-years.
             (Patients who have never smoked cigarettes must be excluded) Pack Years = Number of
             cigarettes/day x years of smoking 20 cigarettes/pack

          4. All patients must have a diagnosis of Chronic Obstructive Pulmonary Disease (COPD)
             (P95-4381), and must meet the following spirometric criteria at Visit 1:Relatively
             stable, moderate to severe airway obstruction with a post-bronchodilator Forced
             Expiratory Volume in one second (FEV1) &lt; 80% of predicted normal and FEV1/Forced Vital
             Capacity (FVC) &lt; 70%. Spirometry should be done at baseline and approximately 1/2 hour
             following 4 inhalations of albuterol. Predicted normal values will be calculated
             according to European Coal and Steel Community (ECSC), European Community for Coal and
             Steel (ECCS), (R94-1408). For Height measured in inches Males: FEV1 predicted (L) =
             4.30 x [height (inches) / 39.37]-0.029 x age (yrs) - 2.49 Females: FEV1 predicted (L)
             = 3.95 x [height (inches) / 39.37]-0.025 x age (yrs) - 2.60 For Height measured in
             meters Males: FEV1 predicted (L) = 4.30 x [height (meters)] - 0.029 x age (years)
             -2.49 Females: FEV1 predicted (L) = 3.95 x [height (meters)] - 0.025 x age (years) -
             2.60

          5. Patients must be able to perform all study related procedures and maintain study
             records during the study period as required in the protocol.

          6. Patients must be able to inhale medication in a competent manner from the RESPIMAT
             inhaler and from a metered dose inhaler (MDI).

        Exclusion criteria:

          1. Patients with significant diseases other than COPD will be excluded. A significant
             disease is defined as a disease which in the opinion of the investigator may either
             put the patient at risk because of participation in the study or a disease which may
             influence the results of the study or the patient's ability to participate in the
             study.

          2. Patients with a recent history (i.e., one year or less) of myocardial infarction.

          3. Patients who have been hospitalized or being treated for heart failure within the past
             year.

          4. Patients with clinically unstable or life-threatening cardiac arrhythmia requiring
             intervention or change in drug therapy within the past year.

          5. Patients with a malignancy for which patient has undergone resection, radiation
             therapy or chemotherapy within last five years (patients with fully cured squamous
             cell or treated basal cell carcinoma are allowed).

          6. Patients with a history of life-threatening pulmonary obstruction, or a history of
             cystic fibrosis or clinically evident bronchiectasis.

          7. Patients who have undergone thoracotomy with pulmonary resection. Patients with a
             history of a thoracotomy for other reasons should be evaluated as per exclusion
             criterion No. 1.

          8. Patients with a current diagnosis of asthma.

          9. Patients with a history of significant alcohol or drug abuse.

         10. Patients with known active tuberculosis.

         11. Patients using beta blocker medications are excluded. Cardioselective beta blockers
             are allowed with caution. Beta blocker eye medications for treatment of non-narrow
             angle glaucoma are allowed.

         12. Patients who regularly use daytime oxygen therapy for more than 1 hour per day
             Continuous Positive Airway Pressure (CPAP for sleep apnea is allowed).

         13. Patients using oral corticosteroid medication at a dose in excess of the equivalent of
             10 mg of prednisone per day or 20 mg every other day, except as required for treatment
             of exacerbation during the study.

         14. Pregnant or nursing women.

         15. Women of childbearing potential not using a medically approved means of contraception
             (i.e., oral or injectable contraceptives, intrauterine devices or diaphragm with
             spermicide, or transdermal hormonal patches). Abstinence will not be accepted as a
             medically approved means of contraception. Female patients will be considered to be of
             childbearing potential unless surgically sterilized by hysterectomy or bilateral tubal
             ligation, or post-menopausal for at least two years.

         16. Patients with known hypersensitivity to anticholinergic drugs, any other component of
             the ipratropium bromide/albuterol RESPIMAT solution including Benzalkonium chloride
             (BAC) and Ethylenediaminetetraacetic acid (EDTA) or the ipratropium bromide/albuterol
             Chlorofluorocarbons (CFC) MDI or Hydrofluoroalkane (HFA) components.

         17. Previous participation in this study. (The patient cannot re-enroll into this study.)

         18. Patients who are currently participating in another interventional study.

         19. Patients who have taken an investigational drug within 1 month or 6 half lives
             (whichever is greater) prior to screening.

         20. Patients currently in any pulmonary rehabilitation program or scheduled to participate
             in any such program during the study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1012.62.153 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jasper</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.145 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.156 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.135 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.141 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.155 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.126 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.131 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.144 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.123 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.114 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.124 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.139 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.134 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.115 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.146 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.113 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.157 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dubuque</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.159 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.116 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.148 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.137 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.132 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.117 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Livonia</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.158 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.127 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.129 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.147 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.149 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.112 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.111 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.120 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.150 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.154 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.128 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.130 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.151 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.161 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.109 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.118 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.125 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.140 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.143 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.152 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Killeen</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.122 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Danville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.119 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.142 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.133 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1012.62.101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2009</study_first_submitted>
  <study_first_submitted_qc>November 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2009</study_first_posted>
  <results_first_submitted>April 5, 2012</results_first_submitted>
  <results_first_submitted_qc>April 5, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 1, 2012</results_first_posted>
  <last_update_submitted>October 14, 2014</last_update_submitted>
  <last_update_submitted_qc>October 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Ipratropium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Combivent Respimat</title>
          <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
        </group>
        <group group_id="P2">
          <title>Combivent Inhalation Aerosol</title>
          <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
        </group>
        <group group_id="P3">
          <title>Atrovent + Albuterol Aerosols</title>
          <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="157">2 pats. in Comb. Inh. Aero. and 3 pats. in Atro+Alb not treated and excluded from the Treated Set</participants>
                <participants group_id="P2" count="156">2 pats. in Comb. Inh. Aero. and 3 pats. in Atro+Alb not treated and excluded from the Treated Set</participants>
                <participants group_id="P3" count="157">2 pats. in Comb. Inh. Aero. and 3 pats. in Atro+Alb not treated and excluded from the Treated Set</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
                <participants group_id="P2" count="118"/>
                <participants group_id="P3" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="47"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason (not specified)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Combivent Respimat</title>
          <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
        </group>
        <group group_id="B2">
          <title>Combivent Inhalation Aerosol</title>
          <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
        </group>
        <group group_id="B3">
          <title>Atrovent + Albuterol Aerosols</title>
          <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="157"/>
            <count group_id="B2" value="154"/>
            <count group_id="B3" value="154"/>
            <count group_id="B4" value="465"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.0" spread="8.2"/>
                    <measurement group_id="B2" value="62.6" spread="8.9"/>
                    <measurement group_id="B3" value="63.0" spread="9.3"/>
                    <measurement group_id="B4" value="62.9" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;= 40 to &lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 65 to &lt; 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="97"/>
                    <measurement group_id="B4" value="273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black / African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="143"/>
                    <measurement group_id="B3" value="144"/>
                    <measurement group_id="B4" value="435"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170.6" spread="9.6"/>
                    <measurement group_id="B2" value="170.6" spread="10.4"/>
                    <measurement group_id="B3" value="171.1" spread="10.4"/>
                    <measurement group_id="B4" value="170.8" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking History</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="79"/>
                    <measurement group_id="B4" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking History (pack years)</title>
          <units>pack years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.6" spread="24.5"/>
                    <measurement group_id="B2" value="53.6" spread="29.7"/>
                    <measurement group_id="B3" value="55.6" spread="25.4"/>
                    <measurement group_id="B4" value="54.3" spread="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Chronic Obstructive Pulmonary Disease (COPD) Duration</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.1" spread="6.7"/>
                    <measurement group_id="B2" value="7.3" spread="6.1"/>
                    <measurement group_id="B3" value="7.5" spread="5.8"/>
                    <measurement group_id="B4" value="7.6" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Performance Domain Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 48</title>
        <description>Patient acceptability was assessed with the Performance Domain score from the PASAPQ. The score is a mean of 7 items on a scale from 0 (very dissatisfied) to 100 (very satisfied).</description>
        <time_frame>48 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Performance Domain Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 48</title>
          <description>Patient acceptability was assessed with the Performance Domain score from the PASAPQ. The score is a mean of 7 items on a scale from 0 (very dissatisfied) to 100 (very satisfied).</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.9" spread="1.27"/>
                    <measurement group_id="O2" value="78.3" spread="1.31"/>
                    <measurement group_id="O3" value="81.7" spread="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Combivent Inhalation Aerosol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>9.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>6.02</ci_lower_limit>
            <ci_upper_limit>13.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Atrovent + Albuterol Aerosols</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0009</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.57</ci_lower_limit>
            <ci_upper_limit>9.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance Domain Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 3</title>
        <description>Patient acceptability was assessed with the Performance Domain score from the PASAPQ. The score is a mean of 7 items on a scale from 0 (very dissatisfied) to 100 (very satisfied).</description>
        <time_frame>3 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Performance Domain Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 3</title>
          <description>Patient acceptability was assessed with the Performance Domain score from the PASAPQ. The score is a mean of 7 items on a scale from 0 (very dissatisfied) to 100 (very satisfied).</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.7" spread="1.07"/>
                    <measurement group_id="O2" value="79.4" spread="1.09"/>
                    <measurement group_id="O3" value="77.3" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Combivent Inhalation Aerosol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.29</ci_lower_limit>
            <ci_upper_limit>8.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Atrovent + Albuterol Aerosols</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.41</ci_lower_limit>
            <ci_upper_limit>10.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance Domain Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 12</title>
        <description>Patient acceptability was assessed with the Performance Domain score from the PASAPQ. The score is a mean of 7 items on a scale from 0 (very dissatisfied) to 100 (very satisfied).</description>
        <time_frame>12 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Performance Domain Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 12</title>
          <description>Patient acceptability was assessed with the Performance Domain score from the PASAPQ. The score is a mean of 7 items on a scale from 0 (very dissatisfied) to 100 (very satisfied).</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.9" spread="1.14"/>
                    <measurement group_id="O2" value="78.0" spread="1.15"/>
                    <measurement group_id="O3" value="76.3" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Combivent Inhalation Aerosol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.71</ci_lower_limit>
            <ci_upper_limit>11.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Atrovent + Albuterol Aerosols</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>9.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>6.44</ci_lower_limit>
            <ci_upper_limit>12.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance Domain Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 24</title>
        <description>Patient acceptability was assessed with the Performance Domain score from the PASAPQ. The score is a mean of 7 items on a scale from 0 (very dissatisfied) to 100 (very satisfied).</description>
        <time_frame>24 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Performance Domain Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 24</title>
          <description>Patient acceptability was assessed with the Performance Domain score from the PASAPQ. The score is a mean of 7 items on a scale from 0 (very dissatisfied) to 100 (very satisfied).</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.6" spread="1.15"/>
                    <measurement group_id="O2" value="77.5" spread="1.16"/>
                    <measurement group_id="O3" value="78.9" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Combivent Inhalation Aerosol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>9.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>5.94</ci_lower_limit>
            <ci_upper_limit>12.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Atrovent + Albuterol Aerosols</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.44</ci_lower_limit>
            <ci_upper_limit>10.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance Domain Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 36</title>
        <description>Patient acceptability was assessed with the Performance Domain score from the PASAPQ. The score is a mean of 7 items on a scale from 0 (very dissatisfied) to 100 (very satisfied).</description>
        <time_frame>36 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Performance Domain Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 36</title>
          <description>Patient acceptability was assessed with the Performance Domain score from the PASAPQ. The score is a mean of 7 items on a scale from 0 (very dissatisfied) to 100 (very satisfied).</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="132"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.2" spread="1.22"/>
                    <measurement group_id="O2" value="76.9" spread="1.24"/>
                    <measurement group_id="O3" value="80.5" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Combivent Inhalation Aerosol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>11.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>7.90</ci_lower_limit>
            <ci_upper_limit>14.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Atrovent + Albuterol Aerosols</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.23</ci_lower_limit>
            <ci_upper_limit>11.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 0</title>
        <description>Patient satisfaction was assessed by asking: &quot;Overall, how satisfied are you with your inhaler?&quot;. Responses were made on a scale from 1 (very dissatisfied) to 7 (very satisfied).</description>
        <time_frame>0 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 0</title>
          <description>Patient satisfaction was assessed by asking: &quot;Overall, how satisfied are you with your inhaler?&quot;. Responses were made on a scale from 1 (very dissatisfied) to 7 (very satisfied).</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="154"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="1.21"/>
                    <measurement group_id="O2" value="5.9" spread="1.24"/>
                    <measurement group_id="O3" value="5.8" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 3</title>
        <description>Patient satisfaction was assessed by asking: &quot;Overall, how satisfied are you with your inhaler?&quot;. Responses were made on a scale from 1 (very dissatisfied) to 7 (very satisfied).</description>
        <time_frame>3 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 3</title>
          <description>Patient satisfaction was assessed by asking: &quot;Overall, how satisfied are you with your inhaler?&quot;. Responses were made on a scale from 1 (very dissatisfied) to 7 (very satisfied).</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="0.08"/>
                    <measurement group_id="O2" value="6.1" spread="0.08"/>
                    <measurement group_id="O3" value="5.9" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Combivent Inhalation Aerosol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1167</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>0.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Atrovent + Albuterol Aerosols</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0026</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.13</ci_lower_limit>
            <ci_upper_limit>0.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 12</title>
        <description>Patient satisfaction was assessed by asking: &quot;Overall, how satisfied are you with your inhaler?&quot;. Responses were made on a scale from 1 (very dissatisfied) to 7 (very satisfied).</description>
        <time_frame>12 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 12</title>
          <description>Patient satisfaction was assessed by asking: &quot;Overall, how satisfied are you with your inhaler?&quot;. Responses were made on a scale from 1 (very dissatisfied) to 7 (very satisfied).</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="0.09"/>
                    <measurement group_id="O2" value="6.0" spread="0.09"/>
                    <measurement group_id="O3" value="5.8" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Combivent Inhalation Aerosol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2826</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.11</ci_lower_limit>
            <ci_upper_limit>0.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Atrovent + Albuterol Aerosols</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0013</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.16</ci_lower_limit>
            <ci_upper_limit>0.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 24</title>
        <description>Patient satisfaction was assessed by asking: &quot;Overall, how satisfied are you with your inhaler?&quot;. Responses were made on a scale from 1 (very dissatisfied) to 7 (very satisfied).</description>
        <time_frame>24 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 24</title>
          <description>Patient satisfaction was assessed by asking: &quot;Overall, how satisfied are you with your inhaler?&quot;. Responses were made on a scale from 1 (very dissatisfied) to 7 (very satisfied).</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="0.08"/>
                    <measurement group_id="O2" value="6.0" spread="0.08"/>
                    <measurement group_id="O3" value="5.8" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Combivent Inhalation Aerosol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0023</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.13</ci_lower_limit>
            <ci_upper_limit>0.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Atrovent + Albuterol Aerosols</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>0.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 36</title>
        <description>Patient satisfaction was assessed by asking: &quot;Overall, how satisfied are you with your inhaler?&quot;. Responses were made on a scale from 1 (very dissatisfied) to 7 (very satisfied).</description>
        <time_frame>36 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 36</title>
          <description>Patient satisfaction was assessed by asking: &quot;Overall, how satisfied are you with your inhaler?&quot;. Responses were made on a scale from 1 (very dissatisfied) to 7 (very satisfied).</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="132"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="0.08"/>
                    <measurement group_id="O2" value="6.0" spread="0.09"/>
                    <measurement group_id="O3" value="5.9" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Combivent Inhalation Aerosol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.18</ci_lower_limit>
            <ci_upper_limit>0.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Atrovent + Albuterol Aerosols</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.20</ci_lower_limit>
            <ci_upper_limit>0.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 48</title>
        <description>Patient satisfaction was assessed by asking: &quot;Overall, how satisfied are you with your inhaler?&quot;. Responses were made on a scale from 1 (very dissatisfied) to 7 (very satisfied).</description>
        <time_frame>48 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Satisfaction Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 48</title>
          <description>Patient satisfaction was assessed by asking: &quot;Overall, how satisfied are you with your inhaler?&quot;. Responses were made on a scale from 1 (very dissatisfied) to 7 (very satisfied).</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="0.09"/>
                    <measurement group_id="O2" value="6.1" spread="0.09"/>
                    <measurement group_id="O3" value="6.0" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Combivent Inhalation Aerosol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0673</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.02</ci_lower_limit>
            <ci_upper_limit>0.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Atrovent + Albuterol Aerosols</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0245</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.04</ci_lower_limit>
            <ci_upper_limit>0.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 0</title>
        <description>CCQ symptom domain score assessed patient feelings or limitations due to their COPD on a scale from 0 (not limited) to 6 (totally limited).</description>
        <time_frame>0 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 0</title>
          <description>CCQ symptom domain score assessed patient feelings or limitations due to their COPD on a scale from 0 (not limited) to 6 (totally limited).</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="1.13"/>
                    <measurement group_id="O2" value="2.7" spread="1.23"/>
                    <measurement group_id="O3" value="2.8" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 3</title>
        <description>CCQ symptom domain score assessed patient feelings or limitations due to their COPD on a scale from 0 (not limited) to 6 (totally limited).</description>
        <time_frame>3 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 3</title>
          <description>CCQ symptom domain score assessed patient feelings or limitations due to their COPD on a scale from 0 (not limited) to 6 (totally limited).</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="0.07"/>
                    <measurement group_id="O2" value="2.7" spread="0.07"/>
                    <measurement group_id="O3" value="2.8" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Combivent Inhalation Aerosol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5695</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.24</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Atrovent + Albuterol Aerosols</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3093</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 12</title>
        <description>CCQ symptom domain score assessed patient feelings or limitations due to their COPD on a scale from 0 (not limited) to 6 (totally limited).</description>
        <time_frame>12 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 12</title>
          <description>CCQ symptom domain score assessed patient feelings or limitations due to their COPD on a scale from 0 (not limited) to 6 (totally limited).</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="0.08"/>
                    <measurement group_id="O2" value="2.9" spread="0.08"/>
                    <measurement group_id="O3" value="2.8" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Combivent Inhalation Aerosol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3578</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.31</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Atrovent + Albuterol Aerosols</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7433</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.18</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 24</title>
        <description>CCQ symptom domain score assessed patient feelings or limitations due to their COPD on a scale from 0 (not limited) to 6 (totally limited).</description>
        <time_frame>24 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 24</title>
          <description>CCQ symptom domain score assessed patient feelings or limitations due to their COPD on a scale from 0 (not limited) to 6 (totally limited).</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="0.08"/>
                    <measurement group_id="O2" value="2.8" spread="0.08"/>
                    <measurement group_id="O3" value="2.8" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Combivent Inhalation Aerosol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.524</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.29</ci_lower_limit>
            <ci_upper_limit>0.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Atrovent + Albuterol Aerosols</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3171</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.34</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 36</title>
        <description>CCQ symptom domain score assessed patient feelings or limitations due to their COPD on a scale from 0 (not limited) to 6 (totally limited).</description>
        <time_frame>36 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 36</title>
          <description>CCQ symptom domain score assessed patient feelings or limitations due to their COPD on a scale from 0 (not limited) to 6 (totally limited).</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="132"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="0.09"/>
                    <measurement group_id="O2" value="2.8" spread="0.09"/>
                    <measurement group_id="O3" value="2.7" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Combivent Inhalation Aerosol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2499</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.38</ci_lower_limit>
            <ci_upper_limit>0.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Atrovent + Albuterol Aerosols</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6144</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.31</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 48</title>
        <description>CCQ symptom domain score assessed patient feelings or limitations due to their COPD on a scale from 0 (not limited) to 6 (totally limited).</description>
        <time_frame>48 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical COPD Questionnaire (CCQ) Symptom Domain Score at Week 48</title>
          <description>CCQ symptom domain score assessed patient feelings or limitations due to their COPD on a scale from 0 (not limited) to 6 (totally limited).</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="0.09"/>
                    <measurement group_id="O2" value="2.7" spread="0.09"/>
                    <measurement group_id="O3" value="2.9" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Combivent Inhalation Aerosol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5142</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.16</ci_lower_limit>
            <ci_upper_limit>0.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Atrovent + Albuterol Aerosols</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2691</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.39</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician's Global Evaluation at Week 0</title>
        <description>Physicians evaluated the patient's overall clinical condition on a scale ranging from &quot;poor&quot; (score 1 or 2) to &quot;excellent&quot; (score 7 or 8).</description>
        <time_frame>0 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Physician's Global Evaluation at Week 0</title>
          <description>Physicians evaluated the patient's overall clinical condition on a scale ranging from &quot;poor&quot; (score 1 or 2) to &quot;excellent&quot; (score 7 or 8).</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="154"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="1.18"/>
                    <measurement group_id="O2" value="4.9" spread="1.22"/>
                    <measurement group_id="O3" value="4.9" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician's Global Evaluation at Week 3</title>
        <description>Physicians evaluated the patient's overall clinical condition on a scale ranging from &quot;poor&quot; (score 1 or 2) to &quot;excellent&quot; (score 7 or 8).</description>
        <time_frame>3 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Physician's Global Evaluation at Week 3</title>
          <description>Physicians evaluated the patient's overall clinical condition on a scale ranging from &quot;poor&quot; (score 1 or 2) to &quot;excellent&quot; (score 7 or 8).</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="0.07"/>
                    <measurement group_id="O2" value="5.1" spread="0.07"/>
                    <measurement group_id="O3" value="5.1" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Combivent Inhalation Aerosol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6236</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.23</ci_lower_limit>
            <ci_upper_limit>0.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Atrovent + Albuterol Aerosols</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3342</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician's Global Evaluation at Week 12</title>
        <description>Physicians evaluated the patient's overall clinical condition on a scale ranging from &quot;poor&quot; (score 1 or 2) to &quot;excellent&quot; (score 7 or 8).</description>
        <time_frame>12 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Physician's Global Evaluation at Week 12</title>
          <description>Physicians evaluated the patient's overall clinical condition on a scale ranging from &quot;poor&quot; (score 1 or 2) to &quot;excellent&quot; (score 7 or 8).</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="0.08"/>
                    <measurement group_id="O2" value="5.2" spread="0.08"/>
                    <measurement group_id="O3" value="5.0" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Combivent Inhalation Aerosol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1884</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.36</ci_lower_limit>
            <ci_upper_limit>0.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Atrovent + Albuterol Aerosols</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6978</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.17</ci_lower_limit>
            <ci_upper_limit>0.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician's Global Evaluation at Week 24</title>
        <description>Physicians evaluated the patient's overall clinical condition on a scale ranging from &quot;poor&quot; (score 1 or 2) to &quot;excellent&quot; (score 7 or 8).</description>
        <time_frame>24 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Physician's Global Evaluation at Week 24</title>
          <description>Physicians evaluated the patient's overall clinical condition on a scale ranging from &quot;poor&quot; (score 1 or 2) to &quot;excellent&quot; (score 7 or 8).</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="0.08"/>
                    <measurement group_id="O2" value="5.2" spread="0.08"/>
                    <measurement group_id="O3" value="5.2" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Combivent Inhalation Aerosol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4197</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.32</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Atrovent + Albuterol Aerosols</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3949</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.33</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician's Global Evaluation at Week 36</title>
        <description>Physicians evaluated the patient's overall clinical condition on a scale ranging from &quot;poor&quot; (score 1 or 2) to &quot;excellent&quot; (score 7 or 8).</description>
        <time_frame>36 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Physician's Global Evaluation at Week 36</title>
          <description>Physicians evaluated the patient's overall clinical condition on a scale ranging from &quot;poor&quot; (score 1 or 2) to &quot;excellent&quot; (score 7 or 8).</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="132"/>
                <count group_id="O3" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="0.09"/>
                    <measurement group_id="O2" value="5.2" spread="0.09"/>
                    <measurement group_id="O3" value="5.2" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Combivent Inhalation Aerosol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.299</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.38</ci_lower_limit>
            <ci_upper_limit>0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Atrovent + Albuterol Aerosols</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1404</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.44</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician's Global Evaluation at Week 48</title>
        <description>Physicians evaluated the patient's overall clinical condition on a scale ranging from &quot;poor&quot; (score 1 or 2) to &quot;excellent&quot; (score 7 or 8).</description>
        <time_frame>48 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Physician's Global Evaluation at Week 48</title>
          <description>Physicians evaluated the patient's overall clinical condition on a scale ranging from &quot;poor&quot; (score 1 or 2) to &quot;excellent&quot; (score 7 or 8).</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="0.09"/>
                    <measurement group_id="O2" value="5.3" spread="0.09"/>
                    <measurement group_id="O3" value="5.1" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Combivent Inhalation Aerosol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.463</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.36</ci_lower_limit>
            <ci_upper_limit>0.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Atrovent + Albuterol Aerosols</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3824</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>0.38</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FEV1 at Day 1</title>
        <description>Change from test-day baseline in Forced Expiratory Volume in 1 second (FEV1) at 1 hour post dose on test day 1.</description>
        <time_frame>baseline, day 1</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FEV1 at Day 1</title>
          <description>Change from test-day baseline in Forced Expiratory Volume in 1 second (FEV1) at 1 hour post dose on test day 1.</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="154"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.015"/>
                    <measurement group_id="O2" value="0.21" spread="0.015"/>
                    <measurement group_id="O3" value="0.21" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Combivent Inhalation Aerosol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8282</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.036</ci_lower_limit>
            <ci_upper_limit>0.045</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Atrovent + Albuterol Aerosols</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6587</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.032</ci_lower_limit>
            <ci_upper_limit>0.050</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FEV1 at Week 12</title>
        <description>Change from test-day baseline in Forced Expiratory Volume in 1 second (FEV1) at 1 hour post dose at Week 12</description>
        <time_frame>baseline, 12 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FEV1 at Week 12</title>
          <description>Change from test-day baseline in Forced Expiratory Volume in 1 second (FEV1) at 1 hour post dose at Week 12</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.016"/>
                    <measurement group_id="O2" value="0.19" spread="0.016"/>
                    <measurement group_id="O3" value="0.20" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Combivent Inhalation Aerosol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1185</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.009</ci_lower_limit>
            <ci_upper_limit>0.081</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Atrovent + Albuterol Aerosols</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2651</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.020</ci_lower_limit>
            <ci_upper_limit>0.072</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FEV1 at Week 24</title>
        <description>Change from test-day baseline in Forced Expiratory Volume in 1 second (FEV1) at 1 hour post dose at Week 24</description>
        <time_frame>baseline, 24 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FEV1 at Week 24</title>
          <description>Change from test-day baseline in Forced Expiratory Volume in 1 second (FEV1) at 1 hour post dose at Week 24</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.016"/>
                    <measurement group_id="O2" value="0.21" spread="0.016"/>
                    <measurement group_id="O3" value="0.21" spread="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Combivent Inhalation Aerosol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5852</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.058</ci_lower_limit>
            <ci_upper_limit>0.033</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Atrovent + Albuterol Aerosols</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7242</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.054</ci_lower_limit>
            <ci_upper_limit>0.038</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FEV1 at Week 48</title>
        <description>Change from test-day baseline in Forced Expiratory Volume in 1 second (FEV1) at 1 hour post dose at Week 48</description>
        <time_frame>baseline, 48 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FEV1 at Week 48</title>
          <description>Change from test-day baseline in Forced Expiratory Volume in 1 second (FEV1) at 1 hour post dose at Week 48</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="121"/>
                <count group_id="O3" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.019"/>
                    <measurement group_id="O2" value="0.16" spread="0.019"/>
                    <measurement group_id="O3" value="0.23" spread="0.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0328</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.005</ci_lower_limit>
            <ci_upper_limit>0.110</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Atrovent + Albuterol Aerosols</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8896</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.058</ci_lower_limit>
            <ci_upper_limit>0.050</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FVC at Day 1</title>
        <description>Change from test-day baseline in Forced Vital Capacity (FVC) at 1 hour post dose on test day 1.</description>
        <time_frame>baseline, day 1</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FVC at Day 1</title>
          <description>Change from test-day baseline in Forced Vital Capacity (FVC) at 1 hour post dose on test day 1.</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="154"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="0.026"/>
                    <measurement group_id="O2" value="0.34" spread="0.027"/>
                    <measurement group_id="O3" value="0.36" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Combivent Inhalation Aerosol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.402</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.042</ci_lower_limit>
            <ci_upper_limit>0.105</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Atrovent + Albuterol Aerosols</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.659</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.057</ci_lower_limit>
            <ci_upper_limit>0.090</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FVC at Week 12</title>
        <description>Change from test-day baseline in Forced Vital Capacity (FVC) at 1 hour post dose at Week 12</description>
        <time_frame>baseline, 12 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FVC at Week 12</title>
          <description>Change from test-day baseline in Forced Vital Capacity (FVC) at 1 hour post dose at Week 12</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="0.027"/>
                    <measurement group_id="O2" value="0.31" spread="0.027"/>
                    <measurement group_id="O3" value="0.35" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Combivent Inhalation Aerosol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0893</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.010</ci_lower_limit>
            <ci_upper_limit>0.139</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Atrovent + Albuterol Aerosols</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5424</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.052</ci_lower_limit>
            <ci_upper_limit>0.099</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FVC at Week 24</title>
        <description>Change from test-day baseline in Forced Vital Capacity (FVC) at 1 hour post dose at Week 24</description>
        <time_frame>baseline, 24 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FVC at Week 24</title>
          <description>Change from test-day baseline in Forced Vital Capacity (FVC) at 1 hour post dose at Week 24</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="0.030"/>
                    <measurement group_id="O2" value="0.35" spread="0.030"/>
                    <measurement group_id="O3" value="0.35" spread="0.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Combivent Inhalation Aerosol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6396</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.104</ci_lower_limit>
            <ci_upper_limit>0.064</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Atrovent + Albuterol Aerosols</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6455</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.106</ci_lower_limit>
            <ci_upper_limit>0.066</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FVC at Week 48</title>
        <description>Change from test-day baseline in Forced Vital Capacity (FVC) at 1 hour post dose at Week 48</description>
        <time_frame>baseline, 48 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FVC at Week 48</title>
          <description>Change from test-day baseline in Forced Vital Capacity (FVC) at 1 hour post dose at Week 48</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="121"/>
                <count group_id="O3" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="0.032"/>
                    <measurement group_id="O2" value="0.30" spread="0.033"/>
                    <measurement group_id="O3" value="0.37" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Combivent Inhalation Aerosol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2596</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.038</ci_lower_limit>
            <ci_upper_limit>0.141</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Atrovent + Albuterol Aerosols</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6659</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.112</ci_lower_limit>
            <ci_upper_limit>0.071</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 0</title>
        <description>Mean number of puffs of daily rescue medication use (albuterol use per 24 hour period) in two weeks prior to week 0</description>
        <time_frame>0 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 0</title>
          <description>Mean number of puffs of daily rescue medication use (albuterol use per 24 hour period) in two weeks prior to week 0</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>number of puffs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="2.63"/>
                    <measurement group_id="O2" value="1.5" spread="2.23"/>
                    <measurement group_id="O3" value="1.9" spread="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 3</title>
        <description>Mean number of puffs of daily rescue medication use (albuterol use per 24 hour period) in two weeks prior to week 3</description>
        <time_frame>3 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 3</title>
          <description>Mean number of puffs of daily rescue medication use (albuterol use per 24 hour period) in two weeks prior to week 3</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>number of puffs</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.10"/>
                    <measurement group_id="O2" value="1.8" spread="0.11"/>
                    <measurement group_id="O3" value="1.7" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Combivent Inhalation Aerosol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.476</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.40</ci_lower_limit>
            <ci_upper_limit>0.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Atrovent + Albuterol Aerosols</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6976</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.35</ci_lower_limit>
            <ci_upper_limit>0.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 12</title>
        <description>Mean number of puffs of daily rescue medication use (albuterol use per 24 hour period) in two weeks prior to week 12</description>
        <time_frame>12 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 12</title>
          <description>Mean number of puffs of daily rescue medication use (albuterol use per 24 hour period) in two weeks prior to week 12</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>number of puffs</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="0.14"/>
                    <measurement group_id="O2" value="1.9" spread="0.14"/>
                    <measurement group_id="O3" value="1.7" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Combivent Inhalation Aerosol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9506</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.40</ci_lower_limit>
            <ci_upper_limit>0.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Atrovent + Albuterol Aerosols</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2362</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>0.62</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 24</title>
        <description>Mean number of puffs of daily rescue medication use (albuterol use per 24 hour period) in two weeks prior to week 24</description>
        <time_frame>24 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 24</title>
          <description>Mean number of puffs of daily rescue medication use (albuterol use per 24 hour period) in two weeks prior to week 24</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>number of puffs</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="0.15"/>
                    <measurement group_id="O2" value="2.0" spread="0.15"/>
                    <measurement group_id="O3" value="1.6" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Combivent Inhalation Aerosol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5645</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.30</ci_lower_limit>
            <ci_upper_limit>0.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Atrovent + Albuterol Aerosols</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0163</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.10</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 36</title>
        <description>Mean number of puffs of daily rescue medication use (albuterol use per 24 hour period) in two weeks prior to week 36</description>
        <time_frame>36 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 36</title>
          <description>Mean number of puffs of daily rescue medication use (albuterol use per 24 hour period) in two weeks prior to week 36</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>number of puffs</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="0.15"/>
                    <measurement group_id="O2" value="2.1" spread="0.15"/>
                    <measurement group_id="O3" value="1.8" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Combivent Inhalation Aerosol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4339</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.60</ci_lower_limit>
            <ci_upper_limit>0.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Atrovent + Albuterol Aerosols</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4886</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>0.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 48</title>
        <description>Mean number of puffs of daily rescue medication use (albuterol use per 24 hour period) in two weeks prior to week 48</description>
        <time_frame>48 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Puffs of Daily Rescue Medication Use in Two Weeks Prior to Week 48</title>
          <description>Mean number of puffs of daily rescue medication use (albuterol use per 24 hour period) in two weeks prior to week 48</description>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>number of puffs</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="0.16"/>
                    <measurement group_id="O2" value="2.1" spread="0.16"/>
                    <measurement group_id="O3" value="1.8" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Combivent Inhalation Aerosol</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7637</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.50</ci_lower_limit>
            <ci_upper_limit>0.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Combivent Respimat versus Atrovent + Albuterol Aerosols</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3755</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for baseline and baseline-by-test-day interaction</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.24</ci_lower_limit>
            <ci_upper_limit>0.65</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Having Chronic Obstructive Pulmonary Disease (COPD) Exacerbations</title>
        <time_frame>48 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Having Chronic Obstructive Pulmonary Disease (COPD) Exacerbations</title>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="154"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118" spread="118"/>
                    <measurement group_id="O2" value="113" spread="113"/>
                    <measurement group_id="O3" value="110" spread="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 or more exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Having Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Leading to Hospitalization</title>
        <time_frame>48 weeks</time_frame>
        <population>Treated Set is defined as all patients who were randomized and received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combivent Respimat</title>
            <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
          </group>
          <group group_id="O2">
            <title>Combivent Inhalation Aerosol</title>
            <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
          </group>
          <group group_id="O3">
            <title>Atrovent + Albuterol Aerosols</title>
            <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Having Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Leading to Hospitalization</title>
          <population>Treated Set is defined as all patients who were randomized and received study drug</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="154"/>
                <count group_id="O3" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147" spread="147"/>
                    <measurement group_id="O2" value="148" spread="148"/>
                    <measurement group_id="O3" value="146" spread="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 or more exacerbations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first drug intake until one day after last drug intake</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Combivent Respimat</title>
          <description>ipratropium/albuterol 20/100 micrograms (mcg) 4 per day (qid)</description>
        </group>
        <group group_id="E2">
          <title>Combivent Inhalation Aerosol</title>
          <description>ipratropium bromide and albuterol sulfate 36/206 mcg qid</description>
        </group>
        <group group_id="E3">
          <title>Atrovent + Albuterol Aerosols</title>
          <description>ipratropium bromide 34 mcg, albuterol sulfate 180 mcg qid</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Pituitary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cardiac enzymes increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave inversion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer stage IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Ovarian fibroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="71" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="157"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

